Krystal Biotech, Inc. (KRYS) Business Profile

What it does

Krystal Biotech discovers, develops, manufactures and sells genetic medicines. Its commercial product, VYJUVEK, treats wounds in people with dystrophic epidermolysis bullosa, or DEB, a rare inherited disease that makes skin fragile and prone to blistering and tearing. Krish S. Krishnan is chairman and chief executive officer.

VYJUVEK is a gel applied directly to an open wound. It delivers copies of a gene that provides skin cells with instructions to make type VII collagen, a protein needed to bind layers of skin together. Treatment can be repeated, and administration can take place at home or in a healthcare setting. Depending on local approval and circumstances, a healthcare professional, caregiver or patient can apply it.

Krystal’s technology uses an engineered form of herpes simplex virus-1 as a carrier to deliver genes into cells. The company develops different formulations for delivery to the skin, lungs and eyes, and operates its own manufacturing facilities.

Its development pipeline includes inhaled treatments for cystic fibrosis and another inherited lung disease, an eye-drop treatment for complications of DEB, and candidates for other eye, skin and cancer indications. These candidates are still in clinical development. Krystal also develops aesthetic medicine candidates through its wholly owned subsidiary, Jeune Aesthetics.

How it makes money

Krystal earns product revenue from sales of VYJUVEK. It holds exclusive worldwide commercialization rights and sells the medicine directly in the United States, major European markets and Japan. It uses specialty distributors in other territories.

VYJUVEK is designed for repeat administration rather than as a one-time treatment. Its U.S. label allows a healthcare professional, caregiver or patient to apply it at home or in a healthcare setting. In its clinical study, treatment resumed when a wound reopened. The timing and amount of product sales can nevertheless vary from quarter to quarter.

The revenue Krystal recognizes reflects an estimate of discounts, returns and rebates under its contracts. Pricing and reimbursement arrangements differ by country. The company is negotiating prices in several European markets, and its French launch operates under an early reimbursed access program. Krystal says German pricing accruals reduced sequential net European revenue in the June 2026 quarter despite growth in related vial sales.

Net VYJUVEK product revenue was $389.1 million for the year ended December 31, 2025. Gross margin was 94% for the year ended December 31, 2025. Since launch in August 2023, cumulative net product revenue was $730.3 million.

Krystal’s other medicines are in development rather than generating disclosed product sales. The company is funding clinical trials and manufacturing work for those candidates, including programs that would use inhaled, eye-drop and injectable formulations of its gene-delivery platform.

Customers and how it sells

VYJUVEK is intended for people with DEB. Healthcare providers and third-party payors participate in prescribing and access, while patients or caregivers may administer treatment where permitted.

Krystal commercializes VYJUVEK directly in the United States, major European markets and Japan. It has launched in Germany, France and Japan, and uses regional specialty distributors outside its direct markets. VYJUVEK received U.K. marketing authorization; Krystal says pricing and reimbursement discussions there are ongoing.

Krystal says it has received more than 730 U.S. reimbursement approvals for VYJUVEK and has treated more than 180 patients in Western Europe and Japan. Reimbursement approvals and patients treated are different measures.

Access arrangements vary by country. In France, administration under the early access pathway is currently concentrated in hospitals because of requirements associated with the medicine’s genetically modified organism classification. In Japan, Krystal says prescription-renewal requirements can place a burden on patients during the first year of launch. Further European launches depend on regulatory interactions and pricing negotiations.

Suppliers and costs

Krystal has two in-house commercial-scale manufacturing facilities supporting its gene-therapy platform. It ships VYJUVEK and product candidates globally from its facilities in Pennsylvania. The company also uses third parties for some manufacturing activities and contract research organizations for some clinical development work.

Cost of goods sold includes direct and indirect VYJUVEK manufacturing costs, personnel costs, facility costs and overhead. It can also include certain manufacturing service costs and inventory adjustments. Research and development spending includes clinical trials and preclinical work performed by outside organizations, as well as candidate manufacturing, laboratory supplies, facilities and payroll.

Krystal expects research and development expenses to increase as it makes clinical materials, runs trials, seeks approvals and expands its portfolio. Trial duration and costs are uncertain, and actual costs to complete trials may exceed expectations. The company also expects to incur manufacturing and commercialization expenses as it seeks approvals and prepares for additional product sales.

Competitive position

Krystal competes in biotechnology and gene therapy, where technologies and products continue to develop. No individual competing company is named in the available business descriptions. Krystal says some competitors have greater financial resources and larger research and development organizations, and that its own experience in trials, approvals, manufacturing and commercialization may be more limited.

Before VYJUVEK’s approval, care for DEB was limited to measures intended to relieve symptoms. Krystal contrasts its topical treatment with approaches that use a patient’s own cells to manufacture an individualized therapy. The company says its vector can be administered repeatedly and delivered directly without hospitalization.

Krystal holds exclusive worldwide rights to VYJUVEK and its pipeline candidates. VYJUVEK is approved in the United States, the EU, Japan and the U.K.; EU authorization also brought market exclusivity. Krystal has a patented platform and in-house manufacturing facilities. It says it has surpassed its initial target of 60% penetration of the diagnosed U.S. patient population.

Our reading: VYJUVEK’s approvals, exclusivity and direct commercial presence provide a meaningful established position in DEB, although they do not eliminate competition from other approaches. Our reading: The platform and manufacturing capabilities could support further products, but their competitive strength beyond VYJUVEK depends on candidates succeeding in development.

Growth opportunities

Krystal is seeking to reach more DEB patients and expand VYJUVEK’s geographic availability. The company estimates there are over 3,000 DEB patients in the United States and over 9,000 worldwide. It says about 1,200 U.S. patients were identified as its initial target population and that it plans to broaden its efforts as it approaches that number. Krystal is also pursuing pricing and reimbursement discussions across Europe.

The clinical pipeline offers routes into other diseases. KB407 is an inhaled candidate for cystic fibrosis, and repeat-dose testing is underway in patients who are ineligible for or refractory to modulator therapy. KB408 is being studied for alpha-1 antitrypsin deficiency lung disease. Krystal estimates that over 60,000 patients in the United States and over 250,000 globally have severe disease.

In eye disease, Krystal has completed enrollment of the registrational IOLITE study of KB803 for ocular complications of DEB. Its KB801 study addresses neurotrophic keratitis. Krystal is also testing KB111 for Hailey-Hailey disease and developing KB707 for cancer; the company expects inhaled KB707 for non-small cell lung cancer to enter a registrational study in 2027.

Jeune Aesthetics is developing candidates for aesthetic skin conditions, including KB301 and KB304. Krystal expects to start a Phase 2 study of KB304 in 2027.

Structural risks

• Commercial dependence: Krystal is substantially dependent on VYJUVEK’s commercial success. Sales can fluctuate with the timing and amount of orders, and reduced demand or difficulty commercializing the product could affect revenue.
• Development and approval: Candidates can encounter enrollment delays, unfavorable results, harmful side effects, clinical holds or changes in regulatory requirements. They may not receive approval or be accepted by patients, healthcare providers and payors.
• Pricing and access: International sales depend on country-specific reimbursement and pricing arrangements. Negotiations can affect launch timing and recognized revenue; German pricing accruals reduced sequential net European revenue in the June 2026 quarter.
• Manufacturing and supply: Candidates may not be producible in commercial quantities at acceptable cost. Krystal must maintain manufacturing processes and arrangements with third-party suppliers or manufacturers for clinical supply.
• Capital and execution: Clinical trial costs are unpredictable, and existing funds may not cover every planned trial, approval process or commercial launch. Additional financing may not be available on acceptable terms.

Bottom line

Our reading

Krystal combines a commercial rare-disease medicine with a pipeline built on the same gene-delivery platform. Its present business rests on VYJUVEK, while broader expansion depends on reimbursement negotiations and the progress of unapproved candidates. In-house manufacturing and existing approvals give it capabilities to build on, but clinical development and international access remain consequential uncertainties.